Vivek Kasinath

TL;DR: A nanoparticle (NP) is synthesized as a carrier of anti-CD3, and the conjugation strategy to coat the NP surface with MECA79 mAb (MECA79-anti- CD3-NP) to enhance LN accumulation is optimized to redefine the methods of administering immune therapeutics in transplantation.

TL;DR: It is found that anti-PD-1 NPs undergo internalization by DCs in the spleen, leading to their maturation and the subsequent activation of T cells, which improves the antitumor effect of this agent in the B16-F10 murine melanoma model.

TL;DR: A novel pathway where IRI activates innate immunity, leading to upregulation of antigen specific alloimmunity, resulting in chronic allograft injury is described, and a clinically relevant treatment strategy to overcome the deleterious effect of IRI is described.

TL;DR: Increased understanding of LN architecture, how different LN SCs integrate immunological cues and shape immune responses, and approaches to induce T cell tolerance will help further combat autoimmune diseases and graft rejection.

TL;DR: Using a highly stringent skin transplant model, the GelMA/anti- IL-6 IMB was far superior to systemic anti-IL-6 receptor treatment in prolonging skin allograft survival and its potential utility in treating patients with severe burns.